Cardiovascular Toxicology

, Volume 3, Issue 1, pp 1–3 | Cite as

Biotechnology-derived cardiovascular therapeutics and toxicity


Key words

Biotechnology cardiovascular disease cytokines adenosine agonist thrombin inhibitors PDGF heart failure 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Marafino, B.J. Jr. and Pugsley, M.K. (2003). Commercial development considerations for biotechnology-derived therapeutis. Cardiovasc. Toxicol. 3:5–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Edelberg, J.M., Cai, D., and Xaymardan, M. (2003). Translation of PDGF cardioprotective pathways. Cardiovasc. Toxicol. 3:27–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Weitz, J.I., Barton, J.E., and Bates, E.R. (2003). Directhrombin inhibitors in cardiac disease. Cardiovasc. Toxicol. 3:13–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Maisel, A.S. (2003). Nesiritide: A new therapy for the tretment of heart failure. Cardiovasc. Toxicol. 3:37–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Hayes, E.S. (2003). Adenosine receptors and cardiovascular disease: The adenosine-1 receptor (A1) and A1 selective ligands. Cardiovasc. Toxicol. 3:71–88.PubMedCrossRefGoogle Scholar
  6. 6.
    Pugsley, M.K., Abramova, M., Cole, T., Yang, X., and Ammons, W.S. (2003). Inhibitors of the complement system currently in development for cardiovascular disease. Cardiovasc. Toxicol. 3:43–69.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2003

Authors and Affiliations

  1. 1.Department of Pharmacology and ToxicologyUniversity of LouisvilleLouisville
  2. 2.Jewish Hospital Heart and Lung InstituteUniversity of LouisvilleLouisville
  3. 3.Department of MedicineUniversity of Louisville School of MedicineLouisville

Personalised recommendations